The National Institute of Probiotics Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2010
NCT01257620
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2012

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (3)

bifidobacterium bifidum (1 trial)

chickpea (1 trial)

lactobacillus delbrueckii (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Gastrointestinal Diseases (Phase 3)

Signs and Symptoms, Digestive (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 3